Human TSC403 gene and human ING1L gene

Abstract

This invention provides the TSC403 gene having a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:1, which is a novel gene of great utility particularly in the field of research, diagnosis, therapy, etc. for cancer of the lung, among other diseases. In addition, this invention provides the human ING1L gene comprising a nucleotide sequence coding for the amino acid sequence of SEQ ID NO:4, which is a novel human gene useful for regulating the cell cycle, inhibiting or activating cell proliferation, studies on metabolic aging or apoptosis of cells, pathological exploration, diagnosis and therapy of cancer and other diseases, and screening for the development of new drugs.

1 . A gene having a nucleotide sequence coding for the amino acid sequence shown in SEQ ID NO:1.  
     
     
         2 . A gene which is a polynucleotide selected from among the following (a), (b) and (c): 
 (a) a polynucleotide containing the nucleotide sequence shown in SEQ ID NO:2 or a complementary sequence thereto,    (b) a polynucleotide that hybridizes to said polynucleotide (a) under stringent conditions, and    (c) a polynucleotide having at least 95% homology to a polynucleotide coding for a polypeptide containing the amino acid sequence shown in SEQ ID NO:1.    
     
     
         3 . The gene defined in  claim 1  or  2  which is a human gene.  
     
     
         4 . The gene defined in  claim 2  which has the nucleotide sequence shown in SEQ ID NO:3.  
     
     
         5 . An oligonucleotide having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:2.  
     
     
         6 . A probe comprising a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:2.  
     
     
         7 . A primer comprising a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:2.  
     
     
         8 . A method for diagnosis of cancer which comprises detecting expression of the gene defined in  claim 1  using a probe having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:2 or a primer having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:2.  
     
     
         9 . The method of diagnosis defined in  claim 8  wherein the cancer is a member selected from among cancer of the mammary gland, cancer of the uterine tube, cancer of the esophagus, cancer of the colon, cancer of the rectum, cancer of the thyroid gland, cancer of the parotid gland, cancer of the ureter, cancer of the ovary and cancer of the pancreas.  
     
     
         10 . A diagnostic kit for cancer which comprises a probe having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:2 or a primer having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:2 as an essential component.  
     
     
         11 . A protein having an amino acid sequence shown in SEQ ID NO:1 which is encoded by the gene defined in  claim 1 .  
     
     
         12 . An antibody having a binding affinity for the protein defined in  claim 11 .  
     
     
         13 . A human gene comprising a nucleotide sequence coding for the amino acid sequence shown in SEQ ID NO:4.  
     
     
         14 . A gene which is a polynucleotide selected from among the following (a), (b) and (c): 
 (a) a polynucleotide containing a nucleotide sequence shown in SEQ ID NO:5 or a complementary sequence thereto,    (b) a polynucleotide that hybridizes to said polynucleotide (a) under stringent conditions, and    (c) a polynucleotide having at least 95% homology to a polynucleotide coding for a polypeptide containing the amino acid sequence shown in SEQ ID NO:4.    
     
     
         15 . The gene defined in  claim 14  which is a human gene having the nucleotide sequence shown in SEQ ID NO:6.  
     
     
         16 . An oligonucleotide having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:5.  
     
     
         17 . A probe having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:5.  
     
     
         18 . A primer having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:5.  
     
     
         19 . A method for diagnosis of cancer which comprises detecting expression of the gene defined in  claim 13  using a probe having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:5 or a primer having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:5.  
     
     
         20 . The method of diagnosis defined in  claim 19  wherein the cancer is a member selected from among colorectal cancer, cancer of the esophagus, cancer of the uterine tube and cancer of the stomach.  
     
     
         21 . A diagnostic kit for cancer which comprises a probe having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:5 or a primer having a sequence consisting of at least 15 consecutive nucleotides in the nucleotide sequence shown in SEQ ID NO:2 as an essential component.  
     
     
         22 . A protein having an amino acid sequence of SEQ ID NO:4 which is encoded by the gene defined in  claim 13 .  
     
     
         23 . An antibody having a binding affinity for the protein defined in claim  22 .